drugset / Trial / NCT04759365
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease
Phase 1
Terminated
25 enrolled
Asceneuron Pty Ltd.
Asceneuron S.A. · collabNeuroscience Trials Australia · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
ASN51-101 is a randomized, double-blind, placebo-controlled, phase 1 first in human (FIH) safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) study of oral ASN51 in healthy young adult and elderly subjects and elderly subjects with AD. The study is comprised of three parts (Part 1, Part 2, and Part 3).
Timeline
- Start
- 2021-06-02
- Primary completion
- 2022-08-01
- Completion
- 2022-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASN51 | Unknown | — | Oral |